Quick Read NVO dropped 5% after guiding to peer-average growth through 2030, while VKTX edged higher as capital rotated toward next-gen obesity challengers. SPY gained 0.6% while XLV slipped only slightly, confirming the selloff as Novo Nordisk-specific rather than a broad obesity-sector repricing. Mike Doustdar put the semaglutide patent cliff in writing, with the 2032 U.S. expiry threatening a product driving over half of annual sales. Just released. Our analysts combed the entire stock market and named the ten best stocks to buy right now, and Eli Lilly didn't make the cut. Enter your email to see the names that beat LLY. The report is free. Enter your email and see if any of your stocks made the cut.
Mostramos publicamente o ponto principal. Crie uma conta gratuita para continuar lendo o artigo completo, salva-lo, comenta-lo e conecta-lo ao contexto de mercado e OSINT.